Lundin Law PC ( http://lundinlawpc.com/) announces that it is investigating claims against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (Nasdaq: SPPI) concerning possible violations of federal securities laws. To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at firstname.lastname@example.org. The investigation focuses on a statement by Spectrum that it failed to disclose that the Food & Drug Administration advised it not to submit a New Drug Application for its drug candidate apaziquone back in December of 2012. Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.